Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $29000.0.

  • Intellia Therapeutics' Capital Expenditures fell 9773.26% to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 6859.27%. This contributed to the annual value of $5.8 million for FY2024, which is 5868.43% down from last year.
  • As of Q3 2025, Intellia Therapeutics' Capital Expenditures stood at $29000.0, which was down 9773.26% from $239000.0 recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Capital Expenditures registered a high of $4.5 million during Q3 2021, and its lowest value of $29000.0 during Q3 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $2.5 million (2024), whereas its average is $2.5 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 55014.33% in 2021, then crashed by 9773.26% in 2025.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Capital Expenditures stood at $2.9 million in 2021, then soared by 36.4% to $3.9 million in 2022, then plummeted by 61.15% to $1.5 million in 2023, then crashed by 35.46% to $981000.0 in 2024, then crashed by 97.04% to $29000.0 in 2025.
  • Its Capital Expenditures stands at $29000.0 for Q3 2025, versus $239000.0 for Q2 2025 and $735000.0 for Q1 2025.